US FDA Advisory Committee votes against Cipro dispersion for inhalation


eMediNexus    16 January 2018

The US Food and Drug Administrations (FDAs) Antimicrobial Drugs Advisory Committee has voted against recommending ciprofloxacin dispersion for inhalation (Cipro DI; Linhaliq, Aradigm) for the treatment of non-cystic fibrosis bronchiectasis in patients with chronic lung infections with Pseudomonas aeruginosa.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.